Kyodo Pharmaceutical announced that revenue for the third quarter of 2026 was 168 million yuan, up 10.26% year on year; net profit loss to mother was 15.9.296 million yuan, after deducting loss of 155.942 million yuan in non-net profit. Revenue for the first three quarters of 2026 was $515 million, up 13.08% year on year; net profit loss to mother was 487.71 million yuan, after deducting loss of non-net profit of 48.2596 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.